TNGX surges 14% as shorts hold firm ahead of November print

Tango Therapeutics added 14% in a week to close at $25.25, a move that sets up a genuine tension: the stock is running hard while short interest is climbing, not retreating, and the options market has swung sharply toward protection.

Short interest now covers 33.8% of the free float, up 7% over the past month, with nearly 45.5 million shares sold short. That is a large and growing bet against a company whose share price has more than doubled year-to-date. What makes the positioning unusual is the disconnect in the lending market. Availability is actually loose at around 663%, meaning lenders hold far more shares available to borrow than are currently out on loan. Borrowing costs remain minimal at 0.56% annualised, down 18% over the past month. That combination, high short interest alongside ample and cheap supply, says shorts are not being squeezed out of their positions; they are simply sitting through the pain. Options traders are less relaxed. The put/call ratio is running at 1.51, nearly two standard deviations above its 20-day average of 0.90, a level of downside hedging that sits close to the highest in the past year and which has climbed sharply from readings near 0.55 in late September.

The Street is firmly behind the stock, at least in terms of direction. All 11 analysts covering TNGX carry buy-equivalent ratings, and the consensus target of $44.88 implies 78% upside from the current price. William Blair initiated at Outperform on October 16. JP Morgan began coverage in July at Overweight with a $46 target. Earlier movers like Jefferies upgraded from Hold to Buy in late June, nearly tripling its target to $60. The bull case rests on vopimetostat, Tango's PRMT5 inhibitor, which posted a 92% overall response rate in 12 second- and third-line pancreatic cancer patients, with 90% progression-free survival at six months. Cash of roughly $1 billion, per management guidance through the current operating plan, covers the path to a planned Phase 3 trial. The bear case is blunter: approval probabilities baked into DCF models are aggressive, the PRMT5 space is crowded with well-capitalised competitors, and the company will almost certainly need to raise dilutive capital before any approval.

The activist register adds context worth noting. Aaron Davis holds a Schedule 13D position at 10.0% of the class, filed in January 2025, making him the largest disclosed activist on the register. Third Rock Ventures, the venture backer, has trimmed from 5.85% to 4.74% over three filings through February 2026. Among passive institutional holders, BlackRock added 3.7 million shares in the most recent quarter and FMR (Fidelity) added 2.4 million, both reported as of September 30. T. Rowe Price added 5.3 million shares in the same period, a notably large build for a manager of that size in a name this speculative. On the other side, Adage Capital cut its holding from roughly 9% to 3.4% between August 2025 and August 2026. Stakes are as-last-disclosed around the 5% threshold, and holders dropping below that level may not file again.

Insider activity is routine rather than informative here. The President of R&D, Crystal Adam, has executed monthly option exercise-and-sell cycles under a 10b5-1 plan, selling around 27,000 shares each month at prevailing prices. These are pre-scheduled compensation mechanics, not discretionary conviction trades.

On the day, TNGX gained 7.3%, outpacing correlated peers ERAS (up 7.3%) and RLAY (up 8.0%) but broadly in line with a sector bounce. ORIC was the standout, up 8.3% on the day and 21.8% on the week. The prior four earnings reactions for Tango have all been negative on the day, averaging roughly a 8% decline, with the largest being a 17% drop in May 2026. The next print is scheduled for November 4, two weeks away, and Wikipedia attention has spiked to a z-score of 4.5 against the company's own 90-day history, a sign retail interest has picked up sharply.

The specific thing to watch before November 4 is whether ESMO 2026 data updates for vopimetostat materially change the efficacy picture that 11 analysts are currently modelling, and whether the put/call ratio, already elevated at 1.51, continues its climb as the earnings date closes in.